Taysha Gene Therapies Files 8-K on Agreements and Financials
Ticker: TSHA · Form: 8-K · Filed: Nov 4, 2025 · CIK: 1806310
Sentiment: neutral
Topics: material-agreement, financial-condition, results-of-operations
TL;DR
Taysha Gene Therapies dropped an 8-K detailing new deals and financial health. Check it out.
AI Summary
Taysha Gene Therapies, Inc. filed an 8-K on November 4, 2025, reporting on the entry into a material definitive agreement, results of operations, and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and headquartered in Dallas, Texas.
Why It Matters
This 8-K filing provides crucial updates on Taysha Gene Therapies' material agreements and financial performance, offering insights into the company's operational status and future outlook.
Risk Assessment
Risk Level: medium — 8-K filings can contain significant corporate events, but without specific details on the agreements or financial results, the immediate risk level is moderate.
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Registrant
- November 4, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Dallas, Texas (location) — Principal Executive Offices
- 3000 Pegasus Park Drive, Suite 1430 (address) — Business Address
FAQ
What is the nature of the material definitive agreement reported in this 8-K?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What are the key results of operations and financial condition mentioned?
The 8-K reports on the results of operations and financial condition, but the specific financial details are not included in the excerpt.
When was this 8-K report filed?
This 8-K report was filed on November 4, 2025.
Where is Taysha Gene Therapies, Inc. headquartered?
Taysha Gene Therapies, Inc. is headquartered in Dallas, Texas.
What is the SIC code for Taysha Gene Therapies, Inc.?
The Standard Industrial Classification (SIC) code for Taysha Gene Therapies, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 1,197 words · 5 min read · ~4 pages · Grade level 10.8 · Accepted 2025-11-04 07:12:02
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value TSHA The Nasdaq Stock Mar
- $150 million — aving aggregate sales proceeds of up to $150 million. As of September 30, 2025, the Company
- $12 million — gregate offering price of approximately $12 million pursuant to the Sales Agreement. On N
- $212 million — ng an aggregate offering price of up to $212 million under the Amended Sales Agreement. The
Filing Documents
- d17004d8k.htm (8-K) — 33KB
- d17004dex11.htm (EX-1.1) — 8KB
- d17004dex12.htm (EX-1.2) — 52KB
- d17004dex991.htm (EX-99.1) — 82KB
- 0001193125-25-263543.txt ( ) — 321KB
- tsha-20251104.xsd (EX-101.SCH) — 3KB
- tsha-20251104_lab.xml (EX-101.LAB) — 18KB
- tsha-20251104_pre.xml (EX-101.PRE) — 11KB
- d17004d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Amendment No. 2 to Sales Agreement, dated November 4, 2025, by and between the Company and Leerink Partners LLC. 1.2 Amendment No. 3 to Sales Agreement, dated November 4, 2025, by and among the Company, Goldman Sachs & Co. LLC and Wells Fargo Securities, LLC. 99.1 Press Release, dated November 4, 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Taysha Gene Therapies, Inc. Dated: November 4, 2025 By: /s/ Kamran Alam Kamran Alam Chief Financial Officer